QMS Medical

- The company planned to raise funds through preferential shares but has not closed this yet. - Currently, acquisitions like Saarathi Healthcare are being funded through internal accruals and working capital limits. - No equity funds from preferential allotments or convertible warrants have been received or utilized so far. - For capex related to expansion and diversification, no additional capex or funding is presently required as enough capital has been pumped in earlier. - Hospital division funding will come from internal business cash flows; no external fund infusion is required at this moment. - The company remains open to fundraising but is prioritizing current internal resources to complete ongoing acquisitions and projects before considering new debt or equity fundraisers.

- Current capital investment: QMS is acquiring a 51% stake in Saarathi Healthcare Private Limited with a payout of around INR18 crores, funded through internal accruals and working capital limits (Page 8). - No significant new capex required for current business models as enough funding has already been pumped into the CAMS model (Page 8). - The hospital division expansion will be funded from the company’s own working capital; no external funding needed at this moment (Page 8). - Plans for manufacturing point-of-care products and enhancing marketing and distribution are in pipeline, indicating potential future investments, though nothing concrete yet besides Saarthi (Page 13). - Preferential allotment fundraise was announced but not yet closed; current acquisition executed without those funds (Page 8).

- QMS Medical Allied Services Limited anticipates a 10%-15% annual growth over the next five years, aiming for systematic and sustainable expansion. - Target to grow the service model to INR100 crores revenue in three years. - Aim to increase QMS business revenue to INR300 crores+ within three years. - Growth drivers include devices, point-of-care products, and patient service programs. - Expansion plans in patient service programs by increasing workforce, geographic reach, and client coverage. - Focus on introducing diversified and innovative point-of-care product offerings. - Emphasis on leveraging online platforms, which have already crossed INR10 crores. - B2B business segment recorded nearly INR50 crores, showing strong potential. - Commitment to broadening direct-to-consumer presence, addressing chronic care management solutions. - Collaboration and manufacturing tie-ups for point-of-care products are underway to support growth.

- QMS Medical Allied Services expects a 45% growth this year in their patient service and device segments. - EBITDA surged by 55.83% in FY24, with significant margin expansion, indicating operational efficiency improvement. - PAT increased by 41.14% to INR 9 crores with PAT margin growth of 126 basis points in FY24. - Earnings per share (EPS) rose by 29.23% to INR 5.04 per share in FY24. - Management anticipates returning to EBITDA margins around 16-17% in upcoming quarters after some recent dips. - Growth drivers include expansions in point-of-care devices, patient service programs, and new acquisitions like Saarathi (51% stake). - Long-term revenue growth target: aiming to grow QMS business to INR 300 crores and service model to INR 100 crores in the next 3 years. - The company is focused on innovative collaborations and expanding healthcare service offerings for sustainable profitability.

- The company has been consistently receiving orders, particularly from pharma companies in its primary segment. - They have conducted over 25,000 camps per year, indicating a steady inflow of orders related to patient service programs. - Sales for Q-Devices products are showing good traction with repeat orders from customers. - Ongoing collaborations and pipeline activities, especially in manufacturing and point-of-care devices, suggest future order inflows. - There was a billings slowdown due to new government guidelines affecting margins temporarily, but business is normalizing now. - The acquisition of Saarathi is expected to contribute to revenues starting from Q2 FY25, potentially increasing the order book. - The focus on expanding patient service programs and point-of-care products is expected to drive order growth steadily.